Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor

Genes Chromosomes and Cancer

Volumn 48, Issue 12, 2009, Pages 1037-1050

  Ohshima, Junjiro ^a,b   Haruta, Masayuki ^a   Arai, Yasuhito ^c   Kasai, Fumio ^a   Fujiwara, Yuiko ^a   Ariga, Tadashi ^b   Okita, Hajime ^d   Fukuzawa, Masahiro ^d   Hata, Jun Ichi ^d   Horie, Hiroshi ^d   Kaneko, Yasuhiko ^a,d  

^a SAITAMA CANCER CENTER   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d Japan Wilms Tumor Study Group JWiTS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BISULFITE; LEUCINE; PHENYLALANINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CARCINOGENESIS; CHILD; CHROMOSOME 7; CHROMOSOME 7P; CHROMOSOME DELETION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC EPIGENESIS; GENOME IMPRINTING; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEOX2 GENE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEPHROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SOSTDC1 GENE; TUMOR SUPPRESSOR GENE; UNIPARENTAL DISOMY;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GENE DELETION; GENOMIC IMPRINTING; HOMEODOMAIN PROTEINS; HOMOZYGOTE; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR II; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEINS; WILMS TUMOR;

EID: 70350247612     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20705     Document Type: Article

References (42)

1. Alami J, Williams BR, Yeger H. 2003. Derivation and characterization of a Wilms' tumour cell line, WiT 49. Int J Cancer 107:365-374. (Pubitemid 37266455)
2. Beckwith JB, Palmer NF. 1978. Histopathology and prognosis of Wilms tumor: Results from the First National Wilms' Tumor Study. Cancer 41:1937-1948. (Pubitemid 8335406)
3. Blish KR, Wang W, Willingham MC, Du W, Birse CE, Krishnan SR, Brown JC, Hawkins GA, Garvin AJ, D'Agostino RB, Jr, Torti FM, Torti SV. 2008. A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell 19:457-464.
4. Cortese R, Hartmann O, Berlin K, Eckhardt F. 2008. Correlative gene expression and DNA methylation profiling in lung development nominate new biomarkers in lung cancer. Int J Biochem Cell Biol 40:1494-1508.
5. d'Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, deLorimier A, Fernbach D, Hrabovsky E, Jones B, Kelalis P, Othersen HB, Tefft M, Thomas PRM. 1989. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 64:349-360.
6. Fukuzawa R, Heathcott RW, More HE, Reeve AE. 2007. Sequential WT1 and CTNNB1 mutations and alterations of β-catenin localization in intralobar nephrogenic rests and associated Wilms tumours: Two case studies. J Clin Pathol 60:1013-1016.
7. Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, Reeve AE. 2009. Canonical WNT signalling determines lineage specificity in Wilms tumour. Oncogene 28:1063-1075.
8. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. 1990. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343:774-778. (Pubitemid 20065258)
9. Gorski DH, LePage DF, Patel CV, Copeland NG, Jenkins NA, Walsh K. 1993. Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol 13:3722-3733. (Pubitemid 23157309)
10. Grundy RG, Pritchard J, Scambler P, Cowell JK. 1998. Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour. Oncogene 17:395-400. (Pubitemid 28383016)
11. Haruta M, Arai Y, Sugawara W, Watanabe N, Honda S, Ohshima J, Soejima H, Nakadate H, Okita H, Hata J, Fukuzawa M, Kaneko Y. 2008. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosomes Cancer 47:712-727. (Pubitemid 351847583)
12. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. 1996. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826. (Pubitemid 26296693)
13. Ishiwata I, Ono I, Ishiwata C, Soma M, Nakaguchi T, Ohara K, Hirano M, Ishikawa H. 1991. Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo. Exp Pathol 41:1-9.
14. Itasaki N, Jones CM, Mercurio S, Rowe A, Domingos PM, Smith JC, Krumlauf R. 2003. Wise, a context-dependent activator and inhibitor of Wnt signalling. Development 130:4295-4305. (Pubitemid 37185319)
15. Japanese Society of Pathology. 2008. The committee on histological classification of childhood tumors: Tumors of the kidney. Tokyo: Kanahara Shuppan.
16. Kaneko Y, Homma C, Maseki N, Sakurai M, Hata J. 1991. Correlation of chromosome abnormalities with histological and clinical features in Wilms' and other childhood renal tumors. Cancer Res 51:5937-5942.
17. Kassai Y, Munne P, Hotta Y, Penttilä E, Kavanagh K, Ohbayashi N, Takada S, Thesleff I, Jernvall J, Itoh N. 2005. Regulation of mammalian tooth cusp patterning by ectodin. Science 309:2067-2070.
18. Knudson AG, Jr, Strong LC. 1972. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst 48:313-324.
19. Laurikkala J, Kassai Y, Pakkasjä rvi L, Thesleff I, Itoh N. 2003. Identification of a secreted BMP antagonist, ectodin, integrating BMP, FGF, and SHH signals from the tooth enamel knot. Dev Biol 24:91-105.
20. Li CM, Kim CE, Margolin AA, Guo M, Zhu J, Mason JM, Hensle TW, Murty VV, Grundy PE, Fearon ER, D'Agati V, Licht JD, Tycko B. 2004. CTNNB1 mutations and overexpression of Wnt/ β-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 165:1943-1953. (Pubitemid 39578373)
21. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT. 2007. Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling. Science 316:1043-1046. (Pubitemid 46799493)
22. Nannya Y, Sanada S, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, Ogawa S. 2005. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65:6071-6079. (Pubitemid 40994391)
23. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, Mack S, Kongkham PN, Peacock J, Dubuc A, Ra YS, Zilberberg K, McLeod J, Scherer SW, Rao JS, Eberhart CG, Grajkowska W, Gillespie Y, Lach B, Grundy R, Pollack IF, Hamilton RL, Van Meter T, Carlotti CG, Boop F, Bigner D, Gilbertson RJ, Rutka JT, Taylor MD. 2009. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41:465-472.
24. Patel S, Leal AD, Gorski DH. 2005. The homeobox gene Gax inhibits angiogenesis through inhibition of nuclear factor-jB-dependent endothelial cell gene expression. Cancer Res 65:1414-1424. (Pubitemid 40270170)
25. Perlman EJ, Grosfeld JL, Togasi K, Boccon-Gibod L. 2004. Pathology and genetics of tumours of the urinary system and male genital organs. In: Eble JN, Sauter G, Epstein JI, Sesterhern IA, editors. World Health Organization Classification of Tumours. Lyon: IARC Press. p 48-52.
26. Perlman H, Sata M, Le Roux A, Sedlak TW, Branellec D, Walsh K. 1998. Bax-mediated cell death by the Gax homeoprotein requires mitogen activation but is independent of cell cycle activity. EMBOJ 17:3576-3586. (Pubitemid 28327376)
27. Perotti D, De Vecchi G, Testi MA, Lualdi E, Modena P, Mondini P, Ravagnani F, Collini P, Di Renzo F, Spreafico F, Terenziani M, Sozzi G, Fossati-Bellani F, Radice P. 2004. Germline mutations of the POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14. Hum Mutat 24:400-407. (Pubitemid 39473665)
28. Perotti D, Gamba B, Sardella M, Spreafico F, Terenziani M, Collini P, Pession A, Nantron M, Fossati-Bellani F, Radice P. 2008. Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene 27:4625-4632.
29. Powlesland RM, Charles AK, Malik KT, Reynolds PA, Pires S, Boavida M, Brown KW. 2000. Loss of heterozygosity at 7p in Wilms' tumour development. Br J Cancer 82:323-329. (Pubitemid 30045377)
30. Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber DA, Uejima H, Feinberg AP. 2001. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 93:1698-1703. (Pubitemid 33130258)
31. Renzo FD, Doneda L, Menegola E, Sardella M, De Vecchi G, Collini P, Spreafico F, Fossati-Bellani F, Giavini E, Radice P, Perotti D. 2006. The murine Pou6f2 gene is temporally and spatially regulated during kidney embryogenesis and its human homolog is overexpressed in a subset of Wilms tumors. J Pediatr Hematol Oncol 28:791-797. (Pubitemid 44967673)
32. Rivera MN, Haber DA. 2005. Wilms' tumour: Connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 5:699-712.
33. Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA. 2007. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315:642-645. (Pubitemid 46214707)
34. Ruteshouser EC, Robinson SM, Huff V. 2008. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47:461-470. (Pubitemid 351657181)
35. Smith RC, Branellec D, Gorski DH, Guo K, Perlman H, Dedieu JF, Pastore C, Hahfoudi A, Denéfle P, Isner JM, Walsh K. 1997. p21 CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. Genes Dev 11:1674-1689. (Pubitemid 27300593)
36. Sossey-Alaoui K, Vieira L, David D, Boavida MG, Cowell JK. 2003. Molecular characterization of a 7p15-21 homozygous deletion in a Wilms tumor. Genes Chromosomes Cancer 36:1-6. (Pubitemid 36077376)
37. Sugawara W, Haruta M, Sasaki F, Watanabe N, Tsunematsu Y, Kikuta A, Kaneko Y. 2007. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 49:240-249. (Pubitemid 47236211)
38. Vernon EG, Malik K, Reynolds P, Powlesland R, Dallosso AR, Jackson S, Henthorn K, Green ED, Brown KW. 2003. The parathyroid hormone-responsive B1 gene is interrupted by a t(1;7)(q42;p15) breakpoint associated with Wilms' tumour. Oncogene 22:1371-1380. (Pubitemid 36384599)
39. Vuononvirta R, Sebire NJ, Dallosso AR, Reis-Filho JS, Williams RD, Mackay A, Fenwick K, Grigoriadis A, Ashworth A, Pritchard-Jones K, Brown KW, Vujanic GM, Jones C. 2008. Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clin Cancer Res 14:7635-14764
40. Wang-Wuu S, Soukup S, Bove K, Gotwals B, Lampkin B. 1990. Chromosome analysis of 31 Wilms' tumors. Cancer Res 50: 2768-2793.
41. Yanagita M, Okuda T, Endo S, Tanaka M, Takahashi K, Sugiyama F, Kunita S, Takahashi S, Fukatsu A, Yanagisawa M, Kita T, Sakurai T. 2006. Uterine sensitization-associated gene-1 (USAG-1), a novel BMP antagonist expressed in the kidney, accelerates tubular injury. J Clin Invest 116:70-79. (Pubitemid 43121792)
42. Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B. 2005. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 3:493-502. (Pubitemid 41377639)